Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Results from the recent Scleroderma Lung Study (SLS) show that oral cyclophosphamide (CYC) is better than placebo in preventing the progression of scleroderma-related interstitial lung disease (SSc-ILD) at 12 months but is associated with adverse events. Also, the long-term balance of risk and benefit remains unclear. D Khanna. (Sage Journals) Medical Decision Making, Vol. 28, No. 6, 926-937 (2008). (Also see: Pulmonary Fibrosis)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
No replies to this topic